Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates
are used in bone metastases to keep the cancerous lesion under control in the bone and to
help prevent calcium level elevations in the blood. Cancer cell-culture studies at the
Cleveland Clinic showed that zoledronic acid and radiation together have more cell killing
effect than either one used alone. The purpose of this study is to monitor the healing of
bone lesions when using zoledronic acid together with radiation treatment.